JP2023513833A5 - - Google Patents
Info
- Publication number
- JP2023513833A5 JP2023513833A5 JP2022549318A JP2022549318A JP2023513833A5 JP 2023513833 A5 JP2023513833 A5 JP 2023513833A5 JP 2022549318 A JP2022549318 A JP 2022549318A JP 2022549318 A JP2022549318 A JP 2022549318A JP 2023513833 A5 JP2023513833 A5 JP 2023513833A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- composition
- seq
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978201P | 2020-02-18 | 2020-02-18 | |
| US62/978,201 | 2020-02-18 | ||
| PCT/US2021/018561 WO2021168100A1 (en) | 2020-02-18 | 2021-02-18 | Formulations of human anti-tslp antibodies and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026042471A Division JP2026131038A (ja) | 2020-02-18 | 2026-03-16 | ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513833A JP2023513833A (ja) | 2023-04-03 |
| JP2023513833A5 true JP2023513833A5 (enExample) | 2024-02-27 |
Family
ID=74860588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549318A Pending JP2023513833A (ja) | 2020-02-18 | 2021-02-18 | ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230081261A1 (enExample) |
| EP (1) | EP4106811A1 (enExample) |
| JP (1) | JP2023513833A (enExample) |
| KR (1) | KR20220143699A (enExample) |
| CN (1) | CN115151276A (enExample) |
| AR (1) | AR121368A1 (enExample) |
| AU (1) | AU2021221998A1 (enExample) |
| CA (1) | CA3167975A1 (enExample) |
| CL (1) | CL2022002251A1 (enExample) |
| CO (1) | CO2022013251A2 (enExample) |
| CR (1) | CR20220465A (enExample) |
| IL (1) | IL295511A (enExample) |
| JO (1) | JOP20220193A1 (enExample) |
| MX (1) | MX2022010120A (enExample) |
| PE (1) | PE20230115A1 (enExample) |
| PH (1) | PH12022552132A1 (enExample) |
| TW (1) | TW202144004A (enExample) |
| UY (1) | UY39089A (enExample) |
| WO (1) | WO2021168100A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4145105A1 (de) * | 2021-09-06 | 2023-03-08 | Anacyte Laboratories GmbH | Lösung für die asservierung von zellen |
| CN118215681A (zh) * | 2021-09-18 | 2024-06-18 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1抗原结合片段的组合物及其用途 |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202426485A (zh) * | 2022-10-26 | 2024-07-01 | 美商安進公司 | 抗ｔｓｌｐ抗體組成物及其用途 |
| WO2024146630A1 (zh) * | 2023-01-06 | 2024-07-11 | 江苏恒瑞医药股份有限公司 | 一种tslp抗体治疗哮喘的方法 |
| WO2024238877A1 (en) * | 2023-05-18 | 2024-11-21 | Medimmune, Llc | Treatment of corticosteroid dependent asthma with anti-tslp antibody |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| EP3594356A1 (en) | 2009-11-04 | 2020-01-15 | Merck Sharp & Dohme Corp. | Engineered anti-tslp antibody |
| SI2523688T1 (en) * | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| CN107428828A (zh) | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| EA038332B1 (ru) | 2015-09-09 | 2021-08-10 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
| EP3609917A1 (en) * | 2017-04-12 | 2020-02-19 | Amgen Inc. | Treatment of asthma with anti-tslp antibody |
| MA48461A (fr) * | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
| IL319987A (en) | 2017-11-10 | 2025-06-01 | Amgen Inc | Plungers for drug delivery devices |
| WO2019178151A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| MA53913A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament |
| JP7719714B2 (ja) | 2018-10-15 | 2025-08-06 | アムジエン・インコーポレーテツド | ダンピング機構を有する薬物送達装置 |
-
2021
- 2021-02-18 MX MX2022010120A patent/MX2022010120A/es unknown
- 2021-02-18 EP EP21710848.9A patent/EP4106811A1/en active Pending
- 2021-02-18 WO PCT/US2021/018561 patent/WO2021168100A1/en not_active Ceased
- 2021-02-18 UY UY0001039089A patent/UY39089A/es unknown
- 2021-02-18 KR KR1020227031575A patent/KR20220143699A/ko active Pending
- 2021-02-18 AU AU2021221998A patent/AU2021221998A1/en active Pending
- 2021-02-18 US US17/760,470 patent/US20230081261A1/en active Pending
- 2021-02-18 PE PE2022001777A patent/PE20230115A1/es unknown
- 2021-02-18 CA CA3167975A patent/CA3167975A1/en active Pending
- 2021-02-18 AR ARP210100423A patent/AR121368A1/es unknown
- 2021-02-18 IL IL295511A patent/IL295511A/en unknown
- 2021-02-18 CR CR20220465A patent/CR20220465A/es unknown
- 2021-02-18 JP JP2022549318A patent/JP2023513833A/ja active Pending
- 2021-02-18 PH PH1/2022/552132A patent/PH12022552132A1/en unknown
- 2021-02-18 JO JOP/2022/0193A patent/JOP20220193A1/ar unknown
- 2021-02-18 TW TW110105518A patent/TW202144004A/zh unknown
- 2021-02-18 CN CN202180015035.0A patent/CN115151276A/zh active Pending
-
2022
- 2022-08-18 CL CL2022002251A patent/CL2022002251A1/es unknown
- 2022-09-16 CO CONC2022/0013251A patent/CO2022013251A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7277681B2 (ja) | 抗体処方物 | |
| US20230192873A1 (en) | Method of treating diseases using an il-17 receptor antibody formulation | |
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| AU2009324371B2 (en) | Antibody formulation | |
| KR102546471B1 (ko) | 액상의 약학 조성물 | |
| IL302921A (en) | Anti-vegf protein compositions and methods for producing the same | |
| JP7551822B2 (ja) | 治療用抗体製剤 | |
| WO2015090162A1 (zh) | 一种含有阿达木单抗的药物组合物 | |
| JP2015522524A (ja) | 抗体製剤 | |
| JP2022097600A (ja) | 抗ＴＮＦα抗体の液状製剤 | |
| JP2022512704A (ja) | 抗ｒｓｖ抗体の製剤及びその使用方法 | |
| TW202333770A (zh) | 用ＴＡＣＩ－Ｆｃ融合蛋白治療ＩｇＡ腎病的方法 | |
| WO2022135395A1 (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| JP2020516651A (ja) | 安定的抗ｏｓｍｒ抗体製剤 | |
| JP2023553538A5 (enExample) | ||
| JP2023513312A5 (enExample) | ||
| TW202434295A (zh) | 一種靶向ｔｓｌｐ的單殖株抗體製劑 | |
| TWI866551B (zh) | 穩定抗體組合物 | |
| JP2016088897A (ja) | エタネルセプトの凍結乾燥製剤 | |
| JP2019534287A (ja) | 治療計画 | |
| TW201902461A (zh) | 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法 | |
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| JP2023514721A5 (enExample) | ||
| JP2025516856A (ja) | 抗ｃｄ３８融合タンパク質製剤 | |
| WO2025129029A2 (en) | Combinations of foralumab with glucagon-like peptide 1 (glp-1) agonists or sodium-glucose cotransporter-2 (sglt2) inhibitors and methods of use thereof |